11 / 14 / 2018
To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-January 2019, in which a cost part will be supported by Explicyte.
05 / 17 / 2018
Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.
03 / 15 / 2016
Two former key executives of preclinical CRO Fluofarma will join Explicyte in March 2016. This new brand, powered by ImmuSmol, offers preclinical contract research services in immuno-oncology, and intends to release specialty research services in the field of neurobiology by the end of 2016.